Oncternal to sell zilovertamab, ONCT-808 programs, wind down operations

Written by Emily J. Thompson, Senior Investment Analyst

ONCT%

Updated: Jul 01 2025

0mins

Oncternal Therapeutics Asset Sale: Oncternal Therapeutics has sold its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics for an upfront payment of $3 million, with potential additional payments totaling up to $65 million based on development and sales milestones.
Leadership Changes: Following the asset sale, Craig R. Jalbert has been appointed as President and CEO of Oncternal, taking over the company's operations as it winds down, after the resignation of the previous board and employees.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Oncternal to sell zilovertamab, ONCT-808 programs, wind down operations

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Top Growth Stocks to Buy Now: Nvidia, Amazon, Dutch Bros

Bitcoin's Market Cap Exceeds $1.9 Trillion, Potential to Reach $1.2 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch